Abstract
Abstract: 15 kids (1-3 years old) with recurrent infections received therapy with Broncho-munal (1 capsule/day) from the day 1 till the day 30 after measles vaccination. The control group of 29 kids of the same age did not receive any immunomodulatory therapy after the vaccination. 12 out of 15 (80%) kids in the Broncho-munal group developed no complications after the vaccination compared with 20 out of 29 kids (68,9%) in the control group. The frequency of intercurrent infections was 3,5 times lower in the Broncho-munal group. The kids in the Broncho-munal group developed neither lymphopenia nor leukopenia. They had increased counts of CD25+ and CD20+ cells by the day 30 after the vaccination, prolonged production of the specific antibodies as well as higher geometric mean titers of the anti-measles antibodies on the day 45 after the vaccination. Taken together these observations suggest that Broncho-munal protected from the transitory immunosuppressive effects of the vaccination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
